A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeffrey R Infante, MD
The Sarah Cannon Research Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Charthouse Square, London, United Kingdom
- Facility name not stated
London, United Kingdom
- Facility name not stated
Manchester, United Kingdom
- Facility name not stated
West Smithfield, London, United Kingdom
- Facility name not stated
Scottsdale, Arizona, United States
- Facility name not stated
Denver, Colorado, United States
- Facility name not stated
Sarasota, Florida, United States
- Facility name not stated
Oklahoma City, Oklahoma, United States
- Facility name not stated
Nashville, Tennessee, United States
- Facility name not stated
Dallas, Texas, United States
- Facility name not stated
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2013
- Primary completion
- 30 Jun 2017
- Completion
- 30 Jun 2017
- Last update posted
- 14 Aug 2017
- Registered enrollment
- 180
- Registry id
- NCT02223247
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.